How to Optimize Treatment With Ustekinumab in Inflammatory Bowel Disease: Lessons Learned From Clinical Trials and Real-World Data.

Front Med (Lausanne) · 2021 · PMC7876229 · PMID 33585530

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

In this cohort, no predictive factors were associated with the main outcomes, and only the number of prior anti-TNF agents (≥3 drugs) showed a trend toward a reduced response rate.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.